Nexvet Reports Financial Results For First Quarter Of Fiscal Year 2017
DUBLIN, Ireland, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three month period ended September 30, 2016.
Recent highlights include:
* Advanced preparations for pivotal studies of the anti-NGF mAb therapy frunevetmab for cats and a pivotal safety study of the anti-NGF mAb therapy ranevetmab for dogs
* Initiated a pivotal target animal safety study of frunevetmab in October
* Announced publication of two peer-reviewed articles regarding frunevetmab in the Journal of Veterinary Internal Medicine
* Received cash of $1.62 million in research and development income from the Australian Government in October
Recent highlights include:
* Advanced preparations for pivotal studies of the anti-NGF mAb therapy frunevetmab for cats and a pivotal safety study of the anti-NGF mAb therapy ranevetmab for dogs
* Initiated a pivotal target animal safety study of frunevetmab in October
* Announced publication of two peer-reviewed articles regarding frunevetmab in the Journal of Veterinary Internal Medicine
* Received cash of $1.62 million in research and development income from the Australian Government in October